Silexion Therapeutics Corp

NasdaqGM:SLXN Stock Report

Market Cap: US$1.5m

Silexion Therapeutics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Ilan Hadar

Chief executive officer

US$253.6k

Total compensation

CEO salary percentage72.1%
CEO tenure2.8yrs
CEO ownershipn/a
Management average tenure2.8yrs
Board average tenureless than a year

Recent management updates

Recent updates


CEO

Ilan Hadar (55 yo)

2.8yrs

Tenure

US$253,614

Compensation

Mr. Ilan Hadar, MBA, is Director of Moringa Acquisition Corp from August 21, 2024. Mr. Hadar has been Chief Executive Officer of Silexion Therapeutics Corp (formerly known as Silexion Therapeutics LTD and...


Leadership Team

NamePositionTenureCompensationOwnership
Ilan Hadar
Chairman & CEO2.8yrsUS$253.61kno data
Mirit Hadar
EVP of Finance Affairsless than a yearUS$69.98kno data
Mitchell Shirvan
Chief Scientific & Development Officer2.8yrsUS$206.80kno data

2.8yrs

Average Tenure

55yo

Average Age

Experienced Management: SLXN's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Ilan Hadar
Chairman & CEO1.6yrsUS$253.61kno data
Ruth Alon
Directorless than a yearno datano data
Ilan Levin
Directorless than a yearno datano data
Shlomo Noy
Directorless than a yearno datano data
Amnon Peled
Independent Directorless than a yearno datano data
Avner Lushi
Directorless than a yearno datano data
Dror Abramov
Directorless than a yearno datano data

0.4yrs

Average Tenure

61yo

Average Age

Experienced Board: SLXN's board of directors are not considered experienced ( 0.4 years average tenure), which suggests a new board.


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/17 22:58
End of Day Share Price 2025/01/17 00:00
Earnings2013/12/31
Annual Earnings2013/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Silexion Therapeutics Corp is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nazibur RahmanMaxim Group